{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rubio-Briones J"],"funding":["Government of Aragon (69_23R) and Ministerio de Ciencia, Innovación y Universidades"],"pagination":["e71173"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12420667"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(17)"],"pubmed_abstract":["<h4>Patients and methods</h4>In this multicenter longitudinal study, data from the Spanish Register in AS (AEU-PIEM/2014/0001) were reviewed. The study focused on a cohort of AS patients registered between 2014 and 2019, featuring open inclusion criteria and diverse follow-up strategies.<h4>Results</h4>A total of 3315 AS patients were recruited, with 2881 and 434 categorized into the low and intermediate risk groups based on NCCN grouping at inclusion. The median age was 67 years, and only 11% underwent diagnostic biopsy guided by MRI. The median time between follow-up visits was 6.03 months. Over a median follow-up of 62 months (Q1-3: 43.78-85.58), 37% remained in AS, while 8% transitioned to watchful waiting due to aging or intercurrent disease. Death occurred in 199 (6%) of patients, wi"],"journal":["Cancer medicine"],"pubmed_title":["Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results."],"pmcid":["PMC12420667"],"funding_grant_id":["(PID2023-150234NB-I00)."],"pubmed_authors":["Fumado Ciutat LL","Lopez Gonzalez PA","Garcia Segui A","Gual Frau J","Gonzalez Alfaro A","Hernandez Martinez YE","Gomez-Veiga F","Garcia Barreras S","Gil Fabra JM","Rodrigo Aliaga M","Dolezal P","Garcia Fadrique G","Plata Bello A","Reyes A","Suarez Novo JF","Mayor de Castro J","Chantada Abal V","Fernandez Aparicio T","Guijarro Cascales A","Herrera Imbroda B","Sanchez Rodriguez C","Pallas Costa Y","Sanguedolce F","Cuadras Sole M","Loizaga Iriarte A","Campanario Perez F","Duarte Ojeda JM","Servian P","Quicios Dorado C","Gimenez Bachs JM","Gomez Gomez E","Rubio-Briones J","Wong A","Serrano Uribe JS","Campa Bortolo JM","Congregado Ruiz CB","Rodriguez Garcia N","Pacheco Bru JJ","Bono Arino A","Soto Delgado M","Medrano Llorente P","Moreno Jimenez J","Rodriguez de Ledesma JM","Montesino Semper M","Garcia Rodriguez J","Molina Suarez JL","Hajianfar R","Esteban Escano LM","Mira Moreno A","Vilaseca Cabo A","Borque-Fernando A"],"additional_accession":[]},"is_claimable":false,"name":"Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results.","description":"<h4>Patients and methods</h4>In this multicenter longitudinal study, data from the Spanish Register in AS (AEU-PIEM/2014/0001) were reviewed. The study focused on a cohort of AS patients registered between 2014 and 2019, featuring open inclusion criteria and diverse follow-up strategies.<h4>Results</h4>A total of 3315 AS patients were recruited, with 2881 and 434 categorized into the low and intermediate risk groups based on NCCN grouping at inclusion. The median age was 67 years, and only 11% underwent diagnostic biopsy guided by MRI. The median time between follow-up visits was 6.03 months. Over a median follow-up of 62 months (Q1-3: 43.78-85.58), 37% remained in AS, while 8% transitioned to watchful waiting due to aging or intercurrent disease. Death occurred in 199 (6%) of patients, wi","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-04-20T03:12:02.023Z","creation":"2026-04-20T03:10:01.327Z"},"accession":"S-EPMC12420667","cross_references":{"pubmed":["40926355"],"doi":["10.1002/cam4.71173"]}}